🔴 Tscan Therapeutics is trading 5.5% down amid biotech-sector weakness, with no clear catalyst

Tscan Therapeutics is trading 5.5% lower at $0.28 on October 6, 2026, with no clear company-specific catalyst identified.

• The latest investor-relations release is dated September 2, and the latest filings shown in the provided context are dated October 2.
• Biotech ETF XBI fell 2.50% during the session, while major U.S. indexes rose. Sector weakness may contribute, but the evidence does not establish a direct cause.